Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumoroids in cervical cancer for prediction of neoadjuvant treatment sensitivity
NL-OMON54137Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of paclitaxel, carboplatin and cisplatin in Cervical Cancer (CC), sponsored by Leiden University Medical Center. Primary endpoints: Optimization of ex vivo tumor testing procedures, Success rate of ex vivo drug sensitivity testing and 2 more. Started Mar 2022; status: recruiting.
02
Drugs
paclitaxelcarboplatincisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON54137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54137.